BerGenBio ASA (LSE) · Health Technology. stock live price and technical analysis view. Follow LSE data on Alerta Chart.
Checking data access...
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
With Alerta Chart Pro Terminal, you can follow 4 charts at the same time, see depth (order book) data and set 25 active alerts.
Start for Free